

ERYTECH PHARMA : ANNUAL GENERAL MEETING OF JUNE 24, 2016

Availability of documents related to the annual general meeting

Lyon (France), June 3, 2016 – ERYTECH Pharma (Paris:ERYP) (ADR:EYRY) (Euronext Paris: ERYP), the French biopharmaceutical company developing ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, announced today the modalities for making available the documents for the Annual General Meeting of June 24, 2016.

ERYTECH Pharma’s shareholders are invited to participate to the Annual General Meeting which will take place on June 24, 2016 at 9 am at the InterContinental Paris Le Grand hotel, 2 Rue Scribe, 75009 Paris.

The meeting notice including the agenda and draft resolutions has been published in the “Bulletin des Annonces Légales Obligatoires” (BALO) N°61 of May 20, 2016. The convening notice will be published in the “Bulletin des Annonces Légales Obligatoires” N°69 of June 8, 2016 and in “Le TOUT LYON AFFICHES” of June 8, 2016.

Documents and information related to this meeting are made available to the shareholders pursuant to legal and regulatory conditions and are available on the website www.erytech.com, Section « Investors / Shareholders Meeting / General Meeting 2016 ».

About ERYTECH Pharma and eryasp/GRASPA®: www.erytech.com

ERYTECH Pharma is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases.

Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting markets with high unmet medical needs. Our initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia, or ALL, and acute myeloid leukemia, or AML, by depriving tumors of nutrients necessary for their survival, which is referred to as tumor starvation.

Eryasp consists of an enzyme, L-asparaginase, encapsulated inside donor-derived red blood cells using our proprietary ERYCAPS platform. L-asparaginase depletes asparagine from circulating blood plasma. Asparagine is a naturally occurring amino acid essential for the survival and proliferation of cells within the body, including cancer cells.

Unlike normal cells, cancer cells often lack the enzymes necessary to produce asparagine internally and therefore must obtain this nutrient from circulating blood. If L-asparaginase can remain in the body long enough to sufficiently deplete circulating asparagine, it can result in the starvation and ultimately the death of cancerous cells.

ERYTECH Pharma is listed on Euronext regulated market in Paris. (ISIN code: FR0011471135, ticker: ERYP) and is part of the CAC Healthcare, CAC Pharm. & Bio and Next Biotech indexes.

Contacts

ERYTECH Pharma

Gil Beyen

Chairman and CEO

Tél : 04 78 74 44 38

investors@erytech.com

NewCap.

Investor and press relations

Julien Perez / Emmanuel Huynh

Tél : 01 44 71 98 52

erytech@newcap.fr

